Houston (1)

Blastoid Variant Mantle Cell Lymphoma (1)

CCND1 Protein Overexpression (1)

CD20 Positive (1)

CD5 Positive (1)

FCER2 Negative (1)

Pleomorphic Variant Mantle Cell Lymphoma (1)

Recurrent Mantle Cell Lymphoma (1)

Refractory Mantle Cell Lymphoma (1)

t(11;14)(q13;q32) (1)

Recruiting (1)

phase 2 (1)

M.D. Anderson Cancer Center (1)

National Cancer Institute (NCI) (1)

acalabrutinib (1)

venetoclax (1)

drug (1)

Other (1)

Interventional (1)

fcer2 negative

Showing 1 - 1 of 1

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

Recruiting

Dec 5, 2022